CA2540021A1 - Hcv inhibitors and methods of using them - Google Patents

Hcv inhibitors and methods of using them Download PDF

Info

Publication number
CA2540021A1
CA2540021A1 CA002540021A CA2540021A CA2540021A1 CA 2540021 A1 CA2540021 A1 CA 2540021A1 CA 002540021 A CA002540021 A CA 002540021A CA 2540021 A CA2540021 A CA 2540021A CA 2540021 A1 CA2540021 A1 CA 2540021A1
Authority
CA
Canada
Prior art keywords
quinoline
alkyl
carboxamide
chloro
tetrazolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002540021A
Other languages
English (en)
French (fr)
Inventor
Sambaiah Thota
Ankush Argade
Rajinder Singh
Henry H. Lu
Peiyong Huang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rigel Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2540021A1 publication Critical patent/CA2540021A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA002540021A 2003-09-26 2004-09-27 Hcv inhibitors and methods of using them Abandoned CA2540021A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US50655603P 2003-09-26 2003-09-26
US60/506,556 2003-09-26
US57653604P 2004-06-03 2004-06-03
US60/576,536 2004-06-03
PCT/US2004/031705 WO2005030774A1 (en) 2003-09-26 2004-09-27 Hcv inhibitors and methods of using them

Publications (1)

Publication Number Publication Date
CA2540021A1 true CA2540021A1 (en) 2005-04-07

Family

ID=34396322

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002540021A Abandoned CA2540021A1 (en) 2003-09-26 2004-09-27 Hcv inhibitors and methods of using them

Country Status (5)

Country Link
US (2) US7358259B2 (https=)
EP (1) EP1668009A1 (https=)
JP (1) JP2007506788A (https=)
CA (1) CA2540021A1 (https=)
WO (1) WO2005030774A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005121138A2 (en) * 2004-06-03 2005-12-22 Rigel Pharmaceuticals, Inc. Heterotricyclic compounds for use as hcv inhibitors
JP2009523820A (ja) 2006-01-23 2009-06-25 アミラ ファーマシューティカルス,インコーポレーテッド 5−リポキシゲナーゼの三環系抑制剤
MY172600A (en) 2013-05-31 2019-12-05 Nissan Chemical Ind Ltd Heterocyclic amide compound
CN111285839A (zh) * 2020-02-26 2020-06-16 唐美荣 一种医药中间体6-氨基胡椒醛的制备方法
PE20251588A1 (es) * 2022-11-15 2025-06-16 Lilly Co Eli Agonistas de ahr
CN115850240B (zh) * 2022-12-28 2023-09-19 北京康立生医药技术开发有限公司 一种治疗急性髓系白血病药物奥卢他西尼的合成方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3891653A (en) * 1970-07-08 1975-06-24 Lilly Co Eli Substituted 4-5 dehydro-tetrazolo(1,5-a)quinolenes
GB1347493A (en) * 1971-02-11 1974-02-27 Aspro Nicholas Ltd Benzazine derivatives
US3775417A (en) * 1971-08-05 1973-11-27 Mallinckrodt Chemical Works Selective hydrogenation of tri-and tetrazoloisoquinolines
BE787536A (fr) * 1971-08-16 1973-02-14 Lilly Co Eli Agents de lutte contre les organismes phytopathogenes
US4000151A (en) * 1974-09-11 1976-12-28 The Upjohn Company Triazolyl benzophenone compounds
US4496569A (en) * 1983-03-25 1985-01-29 The Dow Chemical Company Antiallergic (1H-tetrazol-5-yl)tetrazolo[1,5-a]quinolines and derivatives thereof
US4581455A (en) * 1984-10-10 1986-04-08 Merrell Dow Pharmaceuticals Inc. Tetrazolothienopyridines
CN1043644C (zh) * 1994-03-25 1999-06-16 默里尔药物公司 制备(1H-四唑-5-基)四唑并[1,5-a]喹啉和1,8-二氮杂萘的方法
US5741908A (en) * 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines
DK1140935T3 (da) 1998-12-23 2003-09-01 Janssen Pharmaceutica Nv 1,2-anellerede quinolinderivater
EP1162196A4 (en) * 1999-12-27 2003-04-16 Japan Tobacco Inc COMPOUNDS WITH JOINED CYCLES AND THEIR USE AS MEDICAMENTS
JP4974437B2 (ja) * 2000-09-25 2012-07-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルトランスフェラーゼを阻害する6−[(置換フェニル)メチル]−キノリンおよびキナゾリン誘導体
CN1703403A (zh) * 2000-10-02 2005-11-30 詹森药业有限公司 趋代谢的谷氨酸盐受体拮抗剂
CA2448737C (en) * 2001-07-20 2010-06-01 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
MY151199A (en) 2001-11-02 2014-04-30 Rigel Pharmaceuticals Inc Substituted diphenyl heterocycles useful for treating hcv infection
CA2370396A1 (en) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides

Also Published As

Publication number Publication date
WO2005030774A1 (en) 2005-04-07
US7358259B2 (en) 2008-04-15
JP2007506788A (ja) 2007-03-22
EP1668009A1 (en) 2006-06-14
US20070149520A1 (en) 2007-06-28
US20050090521A1 (en) 2005-04-28

Similar Documents

Publication Publication Date Title
AU2007339382B2 (en) 4,5-ring annulated indole derivatives for treating or preventing of HCV and related viral infections
CN107922425B (zh) 制备parp抑制剂、结晶形式的方法及其用途
JP6629218B2 (ja) N−ベンジルトリプタンスリン誘導体、ならびにその調製方法および利用
US20050215614A1 (en) Substituted indoles and their use as hcv inhibitors
US7569580B2 (en) Heterotricyclic compounds for use as HCV inhibitors
JPS62201882A (ja) イソフラボン誘導体
JP2016535788A5 (https=)
AU2014249003A1 (en) Novel compounds and compositions for inhibition of FASN
CA2471348A1 (en) Quinazolinone derivative
KR102214225B1 (ko) 5원 헤테로시클릭 아미드계 wnt 경로 억제제
CN107098886B (zh) 含有哌嗪酮的喹唑啉酮类parp-1/2抑制剂及其制备方法、药物组合物和用途
US7186830B2 (en) Tricyclic 2-pyrimidone compounds useful as HIV reverse transcriptase inhibitors
WO2005058315A1 (en) Novel heterocyclic compounds as ikk2 inhibitors with anti-hbv activity
WO2010082044A1 (en) Unsaturated bicyclic heterocyclic derivatives as smo antagonists
CA2540021A1 (en) Hcv inhibitors and methods of using them
MX2010013630A (es) Derivados triciclicos de indol y metodos de uso de los mismos.
CN117843638B (zh) 基于rsl3诱导gpx4蛋白降解的双功能分子化合物的制备与应用
JP2007506788A5 (https=)
US20190055212A1 (en) Histone demethylase inhibitors
WO2009033396A1 (fr) Composés dithiolopyrrolones, leur préparation et leur utilisation
CN111116551A (zh) 1-氮杂螺[5.5]十一烷-3-酮类及1-氮杂螺[5.5]十一烷-3-醇类化合物
CN113831346A (zh) 多靶点抗肿瘤小分子及其衍生物、制法、药物组合物和应用
KR20250004711A (ko) Gpr35 조절제 및 이의 용도
CN117343064A (zh) 一种具有抗病毒作用的嘧啶衍生物的制备与应用
US20130053396A1 (en) Piperidine and piperazine derivatives as smo antagonists

Legal Events

Date Code Title Description
FZDE Discontinued